Uploaded September 2024 | Updated November 2026, 3 hours ago
In the “ABCs of MOGAD” episode titled, “Meteoroid and cosMOG Clinical Trials for MOGAD Treatments,” Krissy Dilger of SRNA was joined by Dr. Michael Levy. They described MOG antibody disease and its similarities to NMO and MS, explaining current therapeutic options [00:01:56]. Dr. Levy talked about the cosMOG clinical trial, detailing the mechanism and potential of rozanolixizumab, and the criteria for participation [00:04:54]. The discussion also covered the Meteoroid trial and satralizumab as a potential treatment for MOGAD, comparing its design and eligibility criteria with those of cosMOG [00:15:12]. Both trials are actively enrolling participants, with the aim of preventing disease relapses and further expanding treatment options in the future [00:20:50].
*Please note: Rozanolixizumab can now be administered in the home setting.
Michael Levy, MD, PhD is an Associate Professor of Neurology at Massachusetts General Hospital and Research Director of the Division of Neuroimmunology & Neuroinfectious Disease. He completed the MD/PhD program at Baylor College of Medicine with a focus on neuroscience. In 2009, Dr. Levy was appointed to the faculty as Assistant Professor at Johns Hopkins where he started the Neuromyelitis Optica Clinic and Research Laboratory and in 2019 he moved to the Massachusetts General Hospital and Harvard Medical School to develop the research program in neuroimmunology.
Clinically, Dr. Levy specializes in taking care of patients with rare neuroimmunological diseases including neuromyelitis optica, transverse myelitis, MOG antibody disease, acute disseminated encephalomyelitis and optic neuritis. In addition to neuroimmunology clinics, Dr. Levy has a special interest in patients with superficial siderosis of the central nervous system. Dr. Levy is the principal investigator on several clinical studies and drug trials for all of these conditions.
In the laboratory, Dr. Levy’s research focuses on the development of animal models of neuromyelitis optica and transverse myelitis with the goal of tolerization as a sustainable long-term treatment.
00:00 Introduction to the Episode
01:28 Understanding MOG Antibody Disease
02:40 Current Therapies for MOGAD
04:54 Introduction to cosMOG Clinical Trial
05:35 Mechanism and Progress of cosMOG Trial
08:31 Eligibility and Status of cosMOG Trial
15:12 Introduction to Meteoroid Clinical Trial
15:34 Mechanism and Progress of Meteoroid Trial
19:31 Eligibility and Status of Meteoroid Trial
20:50 How to Participate in the Trials
21:57 Conclusion and Final Thoughts
In the “ABCs of MOGAD” episode titled, “Meteoroid and cosMOG Clinical Trials for MOGAD Treatments,” Krissy Dilger of SRNA was joined by Dr. Michael Levy. They described MOG antibody disease and its similarities to NMO and MS, explaining current therapeutic options [00:01:56]. Dr. Levy talked about the cosMOG clinical trial, detailing the mechanism and potential of rozanolixizumab, and the criteria for participation [00:04:54]. The discussion also covered the Meteoroid trial and satralizumab as a potential treatment for MOGAD, comparing its design and eligibility criteria with those of cosMOG [00:15:12]. Both trials are actively enrolling participants, with the aim of preventing disease relapses and further expanding treatment options in the future [00:20:50].
*Please note: Rozanolixizumab can now be administered in the home setting.
Michael Levy, MD, PhD is an Associate Professor of Neurology at Massachusetts General Hospital and Research Director of the Division of Neuroimmunology & Neuroinfectious Disease. He completed the MD/PhD program at Baylor College of Medicine with a focus on neuroscience. In 2009, Dr. Levy was appointed to the faculty as Assistant Professor at Johns Hopkins where he started the Neuromyelitis Optica Clinic and Research Laboratory and in 2019 he moved to the Massachusetts General Hospital and Harvard Medical School to develop the research program in neuroimmunology.
Clinically, Dr. Levy specializes in taking care of patients with rare neuroimmunological diseases including neuromyelitis optica, transverse myelitis, MOG antibody disease, acute disseminated encephalomyelitis and optic neuritis. In addition to neuroimmunology clinics, Dr. Levy has a special interest in patients with superficial siderosis of the central nervous system. Dr. Levy is the principal investigator on several clinical studies and drug trials for all of these conditions.
In the laboratory, Dr. Levy’s research focuses on the development of animal models of neuromyelitis optica and transverse myelitis with the goal of tolerization as a sustainable long-term treatment.
00:00 Introduction to the Episode
01:28 Understanding MOG Antibody Disease
02:40 Current Therapies for MOGAD
04:54 Introduction to cosMOG Clinical Trial
05:35 Mechanism and Progress of cosMOG Trial
08:31 Eligibility and Status of cosMOG Trial
15:12 Introduction to Meteoroid Clinical Trial
15:34 Mechanism and Progress of Meteoroid Trial
19:31 Eligibility and Status of Meteoroid Trial
20:50 How to Participate in the Trials
21:57 Conclusion and Final Thoughts
![1216. Transcutaneous Spinal Stimulation
In this Ask the Expert episode, Dr. GG deFiebre of SRNA was joined by Dr. Rebecca Martin, who detailed the mechanism and benefits of transcutaneous spinal cord stimulation (TSS). Dr. Martin explained how TSS, a non-invasive method, aims to amplify spinal cord excitability and improve neurological functions like movement and sensation [00:01:25]. She contrasted TSS with implanted spinal stimulators, noting their respective applications and advantages [00:02:34]. Dr. Martin shared the promising outcomes of TSS in clinical trials, emphasizing its potential for widespread clinical use, and she urged patients to inquire about it at their clinics [00:05:42]. You can read her groups recent paper here:
Transcutaneous Spinal Cord Stimulation Enables Recovery of Walking in Children with Acute Flaccid Myelitis
https://www.mdpi.com/2227-9067/11/9/1116
Rebecca Martin, OTR/L, OTD, CPAM received her Bachelor of Science in Occupational Therapy from Boston University in 2001 and her Occupational Therapy Doctorate from Rocky Mountain University of Allied Health Professions in 2008. Prior to joining the Kennedy Krieger Institute, Dr. Martin worked in brain injury rehabilitation in Boston, Massachusetts.
Dr. Martin joined Kennedy Krieger in 2005 as a Senior Occupational Therapist in the International Center for Spinal Cord Injury. Since 2010, Dr. Martin has been the Manager of Clinical Education and Training at ICSCI and is responsible for program development, staff training, and oversight of the clinical research program. Dr. Martin speaks nationally on topics related to Activity-Based Rehabilitation; she has taught many continuing education courses for rehabilitation professionals in the areas of neurological pathology, rehabilitation, and research. She has been the principal investigator and co-investigator for grants from the Paralyzed Veterans of America Education Foundation and Department of Defense to develop, promote, and disseminate an activity-based restorative therapy training program and curriculum.
In 2011, Dr. Martin was awarded the Leader in Spinal Cord Injury Care by the International Center for Spinal Cord Injury at Kennedy Krieger. From 2011-2016, Dr. Martin served as a Committee Chair for the annual Contemporary Trends in Spinal Cord Injury Management Symposium at Kennedy Krieger. As a consultant for SwissStim, she has helped create clinical use guidelines for training and documentation. In 2015, Dr. Martin was invited to serve on the NIH and NINDS Committee to establish Pediatric Spinal Cord Injury Common Data Elements.
00:00 Introduction to the Podcast
00:30 Meet Dr. Becca Martin
01:02 Understanding Electrical Stimulation
01:25 What is Transcutaneous Spinal Stimulation (TSS)?
02:34 Comparing Implanted and Transcutaneous Stimulation
04:17 Target Areas for Stimulation
05:42 Research and Applications in Various Conditions
08:32 Clinical Benefits of TSS
16:17 Risks and Contraindications
18:43 Current Research and Future Directions
22:23 Final Thoughts and Encouragement 1216. Transcutaneous Spinal Stimulation](https://i.ytimg.com/vi/wK-rUhVkObw/mqdefault.jpg)
![Ask the Expert 1402. Paraneoplastic Diseases and Rare Neuroimmune Disorders
In this SRNA “Ask the Expert” episode, Krissy Dilger of SRNA spoke with neuroimmunologist Dr. Shailee Shah about paraneoplastic neurologic syndromes—immune-mediated, “off-target” effects of cancer that can affect the brain, spinal cord, or peripheral nerves. Dr. Shah described updated diagnostic criteria and scoring that combine neurologic phenotypes, cancer risk, and high-risk autoantibodies, and she explained how immune checkpoint inhibitors can trigger immune-related neurologic adverse events that don’t always fit classic rules [00:01:48]. She reviewed how these syndromes differ from other autoimmune neurologic disorders and outlined common subacute presentations such as limbic encephalitis, brainstem encephalitis, cerebellar ataxia, seizures, and neuropathies [00:08:09]. Dr. Shah emphasized prompt evaluation with neurologic exam, MRI/EEG/EMG as appropriate, blood and CSF antibody testing, cancer screening, and coordinated oncologic and immunosuppressive treatment to prevent worsening disability [00:17:24].
Shailee Shah, MD is a Clinical Assistant Professor in the Neuroimmunology Division with Northwestern Medicine and Northwestern University. She is an autoimmune neurologist with expertise in the management of paraneoplastic and autoimmune neurological diseases. She also treats rare neuroimmunological diseases such as neuromyelitis optica and MOG associated disease. She is co-director of the Northwestern Medicine Paraneoplastic Neurological Disease Clinic.
00:00 Welcome and Guest Intro
00:58 What Is Paraneoplastic
01:48 New Criteria and Antibodies
04:59 Diagnostic Challenges and ICI
08:09 Paraneoplastic vs Autoimmune
10:22 How Common Are They
13:03 Early Symptoms to Watch
17:24 When to Seek Care
19:09 Testing and Workup
24:20 Paraneoplastic Myelitis
27:55 Delays and Specialty Centers
31:38 Cancer Link and Treatment
37:16 Changing Therapies
38:19 Recovery and Prognosis
39:58 Patient Advice and Hope
42:52 Closing Ask the Expert 1402. Paraneoplastic Diseases and Rare Neuroimmune Disorders](https://i.ytimg.com/vi/wPs7F9KpKwc/mqdefault.jpg)
![2024 RNDS | MOG Antibody Disease (MOGAD) and Acute Disseminated Encephalomyelitis (ADEM)
You can view the presentation slides here:
https://files.wearesrna.org/symposia/2024_rnds/slides/2024RNDS_Schreiner.pdf
At the 2024 RNDS, Drs. Teri Schreiner, Michael Levy, and Grace Gombolay shared their expertise in pediatric and adult neuroimmunology, focusing on diagnosing and managing acute disseminated encephalomyelitis (ADEM) and MOG antibody disease (MOGAD) [00:00:53]. Dr. Schreiner provided a detailed overview of ADEM, including typical symptoms, diagnostic criteria, and treatment options [00:05:24]. Dr. Gombolay then explained MOGAD, comparing its symptoms and progression to those of other neuroimmune disorders such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) [00:17:24]. The session included a segment where panelists addressed audience questions about treatment efficacy, symptom management, and the challenges of insurance coverage for treatments like IVIG [00:28:36]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
00:00 Welcome and Introductions
02:15 Overview of ADEM
12:15 Understanding MOGAD
17:24 Comparing ADEM, MOGAD, and MS
21:22 Treatment and Recovery
28:36 Questions and Discussions
40:21 Understanding Drug Delivery Systems
40:29 Steroid Dosing Mysteries
40:54 Steroid Side Effects and Alternatives
41:41 MRI Findings in Neuroimmunology
42:59 Diagnosing MOGAD vs. NMOSD
46:27 International Perspectives on MOGAD Treatment
49:24 Managing Fatigue in Neuroimmune Disorders
01:02:39 Challenges with Insurance for IVIG Treatment
01:09:58 Navigating Relapses and Treatment Options 2024 RNDS | MOG Antibody Disease (MOGAD) and Acute Disseminated Encephalomyelitis (ADEM)](https://i.ytimg.com/vi/xOmLucFA5vg/mqdefault.jpg)

![2024 RNDS | Transverse Myelitis (TM) and Acute Flaccid Myelitis (AFM)
At the 2024 RNDS, Drs. Leslie Benson, Carlos A. Pardo, and Benjamin Greenberg discussed transverse myelitis (TM) and acute flaccid myelitis (AFM), addressing key questions from the audience [00:00:12]. The session covered symptoms, treatment options, and lifestyle adjustments to manage conditions better [00:02:15]. The experts also emphasized the importance of proper diagnosis, sleep hygiene, and the role of rehabilitation medicine in managing fatigue and spasticity [00:15:03]. Additionally, the panel delved into both the potential and current limitations of stem cell therapy for treating these disorders [00:40:40]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
00:00 Introduction and Session Overview
00:29 Meet the Experts: Dr. Benjamin Greenberg, Dr. Leslie Benson, and Dr. Carlos Pardo
01:10 Interactive Discussion: Your Questions Matter
04:49 Understanding Fatigue in Myelitis
06:34 Managing Fatigue: Strategies and Solutions
10:26 Energy Conservation Techniques
14:51 Medication Management and Side Effects
32:41 Spasticity: Non-Prescription Approaches
40:40 Stem Cell Therapy: Hopes and Realities
47:16 The Challenges of Stem Cell Therapy
48:16 Patient Experiences and Misconceptions
49:06 Scientific Skepticism and Cynicism
51:40 The Role of SRNA in Patient Advocacy
52:37 Managing Long-Term Care for TM
57:48 Muscle Spasticity and Treatment Options
01:14:39 Understanding Myelitis: Diagnosis and Root Causes
01:26:30 Final Q&A and Closing Remarks 2024 RNDS | Transverse Myelitis (TM) and Acute Flaccid Myelitis (AFM)](https://i.ytimg.com/vi/yC0WJfnLNjo/mqdefault.jpg)

![Ask the Expert | Research Edition 1406. Q Study Updates | Expanded Inclusion Criteria & What’s Next
Krissy Dilger of SRNA hosted Dr. Benjamin Greenberg of UT Southwestern to share updates on the Q Study, a Phase 1 trial assessing the safety and feasibility of transplanting human glial restricted progenitor cells into the spinal cord of people who have been diagnosed with transverse myelitis (TM). Dr. Greenberg cautioned the audience against stem cell tourism [00:03:03]. He described the decades-long development of the cell line and safety monitoring for this study [00:01:35]. He reported no safety signals prompting a trial pause and noted the FDA-approved expansion of eligibility from non-ambulatory participants to those who can walk with assistance, while efficacy results were not yet being shared [00:08:31]. Finally, Dr. Greenberg outlined potential next steps, including Phase 2 studies and expanded populations (e.g., MOGAD and NMOSD diagnoses), as well as future targets [00:17:02].
Benjamin M. Greenberg, MD, MHS is a Professor and the Cain Denius Scholar in Mobility Disorders in the Department of Neurology [https://utswmed.org/why-utsw/departments/neurology/] at UT Southwestern Medical Center in Dallas, Texas. He currently serves as the Vice Chair of Translational Research and Strategic Initiatives for the Department of Neurology. He is also the interim Director of the Multiple Sclerosis Center [https://utswmed.org/locations/aston/multiple-sclerosis-and-neuroimmunology-clinic/] and the Director of the Neurosciences Clinical Research Center. In addition, he serves as Director of the Transverse Myelitis and Neuromyelitis Optica Program and the Pediatric Demyelinating Disease Program at Children’s Medical Center [https://www.childrens.com/specialties-services/specialty-centers-and-programs/neurology/demyelinating-disease-program].
Dr. Greenberg earned his medical degree at Baylor College of Medicine before completing an internal medicine internship at Chicago’s Rush Presbyterian-St. Luke’s Medical Center. He performed his neurology residency at the Johns Hopkins School of Medicine. He also holds an M.H.S. in molecular microbiology and immunology from the Bloomberg School of Public Health, as well as a bachelor’s degree in the history of medicine – both from Johns Hopkins. Prior to his recruitment to UT Southwestern in 2009, Dr. Greenberg was on the faculty of the Johns Hopkins Division of Neuroimmunology, serving as the Director of the Encephalitis Center and Co-Director of the nation’s first dedicated Transverse Myelitis Center.
Dr. Greenberg splits his clinical time between adult and pediatric patients at William P. Clements Jr. and Zale Lipshy University Hospitals, Parkland, and Children’s Medical Center. His research focuses on better diagnosing, prognosticating, and treating demyelinating diseases and nervous system infections. He also coordinates clinical trials to evaluate new treatments to prevent neurologic damage and restore function to affected patients.
00:00 Welcome and Guest Intro
01:35 Origins of Q Study
02:46 Getting Cells Into Cord
04:49 Phase One Trial Design
06:31 Safety and Efficacy Measures
08:31 Eligibility Expanded Criteria
11:39 Screening and Selection
14:05 Travel and Site Logistics
15:15 Early Safety Findings
17:02 Next Steps After Phase One
19:01 Beyond Idiopathic Myelitis
23:07 Damage Differences by Disease
25:20 Optic Nerve and Brain Targets
27:29 Expected Outcomes and Vision
28:58 Final Thanks Ask the Expert | Research Edition 1406. Q Study Updates | Expanded Inclusion Criteria & What’s Next](https://i.ytimg.com/vi/zs6w6dtqr3U/mqdefault.jpg)